» Articles » PMID: 25621161

Possible Role of Lysophosphatidic Acid in Rat Model of Hypoxic Pulmonary Vascular Remodeling

Overview
Journal Pulm Circ
Publisher Wiley
Specialty Pulmonary Medicine
Date 2015 Jan 27
PMID 25621161
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

Pulmonary hypertension is characterized by cellular and structural changes in the vascular wall of pulmonary arteries. We hypothesized that lysophosphatidic acid (LPA), a bioactive lipid, is implicated in this vascular remodeling in a rat model of hypoxic pulmonary hypertension. Exposure of Wistar rats to 10% O2 for 3 weeks induced an increase in the mean serum levels of LPA, to 40.9 (log-detransformed standard deviations: 23.4-71.7) μM versus 21.6 (11.0-42.3) μM in a matched control animal group (P = 0.037). We also observed perivascular LPA immunohistochemical staining in lungs of hypoxic rats colocalized with the secreted lysophospholipase D autotaxin (ATX). Moreover, ATX colocalized with mast cell tryptase, suggesting implication of these cells in perivascular LPA production. Hypoxic rat lungs expressed more ATX transcripts (2.4-fold) and more transcripts of proteins implicated in cell migration: β2 integrin (1.74-fold), intracellular adhesion molecule 1 (ICAM-1; 1.84-fold), and αM integrin (2.70-fold). Serum from the hypoxic group of animals had significantly higher chemoattractant properties toward rat primary lung fibroblasts, and this increase in cell migration could be prevented by the LPA receptor 1 and 3 antagonists. LPA also increased adhesive properties of human pulmonary artery endothelial cells as well as those of human peripheral blood mononuclear cells, via the activation of LPA receptor 1 or 3 followed by the stimulation of gene expression of ICAM-1, β-1, E-selectin, and vascular cell adhesion molecule integrins. In conclusion, chronic hypoxia increases circulating and tissue levels of LPA, which might induce fibroblast migration and recruitment of mononuclear cells in pulmonary vasculature, both of which contribute to pulmonary vascular remodeling.

Citing Articles

Possible Involvement of Lysophospholipids in Severe Asthma as Novel Lipid Mediators.

Kume H, Kazama K, Sato R, Sato Y Biomolecules. 2025; 15(2).

PMID: 40001485 PMC: 11852450. DOI: 10.3390/biom15020182.


Involvement of Lysophospholipids in Pulmonary Vascular Functions and Diseases.

Kume H, Harigane R, Rikimaru M Biomedicines. 2024; 12(1).

PMID: 38255229 PMC: 10813361. DOI: 10.3390/biomedicines12010124.


FAM171B as a Novel Biomarker Mediates Tissue Immune Microenvironment in Pulmonary Arterial Hypertension.

Qu L, Luo W, Yan Z, Liu W Mediators Inflamm. 2022; 2022:1878766.

PMID: 36248192 PMC: 9553458. DOI: 10.1155/2022/1878766.


Mast Cell-Tumor Interactions: Molecular Mechanisms of Recruitment, Intratumoral Communication and Potential Therapeutic Targets for Tumor Growth.

Segura-Villalobos D, Ramirez-Moreno I, Martinez-Aguilar M, Ibarra-Sanchez A, Munoz-Bello J, Anaya-Rubio I Cells. 2022; 11(3).

PMID: 35159157 PMC: 8834237. DOI: 10.3390/cells11030349.


Preventing the Increase in Lysophosphatidic Acids: A New Therapeutic Target in Pulmonary Hypertension?.

Duflot T, Tu L, Leuillier M, Messaoudi H, Groussard D, Feugray G Metabolites. 2021; 11(11).

PMID: 34822442 PMC: 8621392. DOI: 10.3390/metabo11110784.


References
1.
von Hundelshausen P, Weber C . Platelets as immune cells: bridging inflammation and cardiovascular disease. Circ Res. 2007; 100(1):27-40. DOI: 10.1161/01.RES.0000252802.25497.b7. View

2.
Tomsig J, Snyder A, Berdyshev E, Skobeleva A, Mataya C, Natarajan V . Lipid phosphate phosphohydrolase type 1 (LPP1) degrades extracellular lysophosphatidic acid in vivo. Biochem J. 2009; 419(3):611-8. PMC: 2677185. DOI: 10.1042/BJ20081888. View

3.
Jurk K, Kehrel B . Platelets: physiology and biochemistry. Semin Thromb Hemost. 2005; 31(4):381-92. DOI: 10.1055/s-2005-916671. View

4.
Watsky M, Weber K, Sun Y, Postlethwaite A . New insights into the mechanism of fibroblast to myofibroblast transformation and associated pathologies. Int Rev Cell Mol Biol. 2010; 282:165-92. DOI: 10.1016/S1937-6448(10)82004-0. View

5.
Tokumura A, Carbone L, Yoshioka Y, Morishige J, Kikuchi M, Postlethwaite A . Elevated serum levels of arachidonoyl-lysophosphatidic acid and sphingosine 1-phosphate in systemic sclerosis. Int J Med Sci. 2009; 6(4):168-76. PMC: 2695151. DOI: 10.7150/ijms.6.168. View